Pre-Surgery Immunotherapy Shows Promising Results in Bowel Cancer

The Dawn of Neoadjuvant Immunotherapy: A Paradigm Shift in Bowel Cancer Treatment

For decades, the gold standard for treating bowel cancer has followed a predictable, often grueling path: surgery first, followed by aggressive chemotherapy. While effective, this approach often leaves a significant gap in long-term recovery, with roughly 25% of patients facing a relapse within three years.

However, new evidence from the NEOPRISM-CRC trial, led by University College London and University College London Hospitals, suggests we are entering a new era. By flipping the script and administering immunotherapy before surgery, clinicians are seeing results that could redefine the survival trajectory for thousands of patients.

Precision Medicine: Moving Beyond “One Size Fits All”

The most compelling aspect of this shift isn’t just the drug used—Pembrolizumab—but the precision with which it is monitored. The integration of personalized blood tests to track tumor DNA (known as liquid biopsies) allows doctors to see if a treatment is working in real-time, rather than waiting for a post-operative scan.

The Role of Immune Profiling

By analyzing the immune profile of tumor tissue, researchers can now forecast which patients are most likely to respond to immunotherapy. This prevents patients who wouldn’t benefit from the drug from undergoing unnecessary treatment, while intensifying care for those at higher risk.

According to Kai-Keen Shiu, these diagnostic tools enable clinicians to tailor treatment intensity, potentially reducing the toxicity of therapy for low-risk patients while ensuring high-risk individuals receive the most aggressive intervention possible.

Future Trends: Where Is Oncology Heading?

The success of the NEOPRISM-CRC trial points toward several emerging trends in oncology that will likely dominate the next decade of cancer care:

• Neoadjuvant Dominance: We will likely see more “pre-surgery” (neoadjuvant) therapies. By shrinking tumors and clearing micrometastases before the surgeon even enters the operating room, the likelihood of complete pathological response increases.
• The Complete of “Blanket” Chemotherapy: As immunotherapy and targeted biologicals become more precise, the reliance on broad-spectrum chemotherapy—which affects the entire body—may diminish in favor of treatments that only target cancer cells.
• Real-Time Monitoring: The use of circulating tumor DNA (ctDNA) will move from clinical trials to standard practice, allowing for “molecular recurrence” detection months before a tumor is visible on an MRI or CT scan.

Analyzing the Data: Why These Results Matter

To understand the impact, we must look at the numbers. In the NEOPRISM-CRC trial, 59% of patients showed no detectable cancer after the combination of nine weeks of Pembrolizumab and surgery. More impressively, after 33 months of follow-up, none of the participants experienced recurrence.

When compared to the standard surgery-then-chemo route—where a quarter of patients typically relapse—the durability of this new approach is striking. While the sample size of 32 patients is specific, the 100% non-recurrence rate in this cohort provides a powerful proof-of-concept for personalized immunotherapy.

Frequently Asked Questions